Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent ...

Eli Lilly has announced that the company will present data from studies of Jaypirca (pirtobrutinib) at the 66th American ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the ...

Analyst Sel Hardy is bullish on several late-stage Eli Lilly drugs, particularly pirtobrutinib for certain forms of leukemia and lymphoma and tirzepatide for sleep apnea and cardiology.

In selected patients who do not tolerate the non-covalent second-generation BTK inhibitors in the first or second line, he said, “I move quickly to the covalent BTKi pirtobrutinib,” based on ...

Antibiotic therapy with moxifloxacin in this large-scale PMS study resulted in rapid improvement in symptoms of acute sinusitis. Moxifloxacin was remarkably well tolerated in the examined patient ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

INDIANAPOLIS, Nov. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine ...

Analyst Sel Hardy says Eli Lilly has several bullish catalysts ahead in 2024 and beyond, including Alzheimer's disease drug donanemab, cancer drug pirtobrutinib and sleep apnea and cardiology drug ...